N-Power Medicine Closes $32 Million Series B to Expand Community Oncology Network and ProECA Platform
核心洞察
N-Power Medicine (搜索) closed a $32 million Series B financing round, with Labcorp Venture Fund (搜索) joining as a new strategic investor alongside Merck Global Health Innovation Fund (搜索) and Innovatus Capital Partners (搜索).
The funding will expand the company's community oncology research network and accelerate adoption of ProECA, its first-of-its-kind Prospective External Control Arms platform.
ProECA enables smaller, faster trials with reduced reliance on randomization, cutting enrollment requirements, shortening timelines, and lowering development costs.
N-Power Medicine (搜索), a company reinventing oncology drug development and community cancer patient care, announced the close of a $32 million Series B financing round to fuel its next phase of growth, including expansion of its community oncology network, deepening pharmaceutical partnerships, and continued investment in product development.
The round includes new strategic investor Labcorp Venture Fund (搜索), along with continued participation from Merck Global Health Innovation Fund (搜索) (Merck GHI), Innovatus Capital Partners (搜索), and a leading U.S.-based biotech investor. Labcorp Venture Fund's investment marks the second strategic investment from a healthcare industry leader, following Merck GHI, further validating N-Power's novel approach to oncology drug development and broadened access to clinical research in community oncology.
A First-of-Its-Kind Prospective External Control Arm Platform
At the core of N-Power's innovation is the Prospective External Control Arm (ProECA) platform, which the company describes as the first of its kind. ProECA enables smaller, faster trials with reduced reliance on randomization, and allows for better informed early development decision-making.
ProECAs are standalone, prospective, trial-grade external control arms generated in routine care. By leveraging everyday cancer care data, the platform aims to reduce dependence on traditional randomized control arms in clinical trials. This approach cuts patient enrollment requirements, shortens trial timelines, and lowers development costs, while expanding opportunities for more patients to participate in cancer research.
"By bringing prospective external control arm programs directly into everyday cancer care, we dramatically speed up drug development while giving many more oncologists and patients access to research and innovative therapies," said Mark Lee, M.D., Ph.D., N-Power Co-Founder and Chief Executive Officer.
Expanding Across Community Oncology
N-Power's first ProECA, focused on non-small cell lung cancer (搜索) (NSCLC), is operational at more than 40 sites across its community oncology research network, spanning multiple large community-based health systems. Several pharmaceutical and biotech partners use the NSCLC ProECA today to accelerate their early development and Phase 4 programs.
The company plans to launch ProECA in colorectal cancer (搜索) and prostate cancer (搜索) later this year, further extending its impact on oncology research and patient outcomes.
Strategic Validation and Investor Support
Labcorp is a global leader of innovative and comprehensive laboratory services, and, through the Labcorp Venture Fund (搜索), invests in innovative technologies that advance more personalized, accessible, and data-driven healthcare.
"N-Power's innovative approach has the potential to accelerate oncology drug development while expanding access to clinical research in community care settings," said Megann Vaughn Watters, Managing Director, Labcorp Venture Fund (搜索). "We are excited to support the company as it scales this model and broadens its impact for patients and providers."
"We've built a model that creates value for drug developers, community oncologists, and cancer patients," said Dr. Lee. "With Labcorp Venture Fund (搜索) joining our existing investors, this financing lets us scale and set a new standard for how oncology drug development gets done."
N-Power Medicine (搜索) has built a national network of community oncology centers, creating the first "always-on" ProECA platform that enables drug developers to reduce or replace randomized control arms and run faster, smaller, more efficient clinical trials, while simultaneously expanding access to clinical research and innovation for physicians and patients in the communities where they live.